Alchemia cancer news

Audeo Oncology Inc., Alchemia's newly formed U.S. subsidiary, said it plans to raise up to $60 million in an IPO on NASDAQ underwritten by Leerink and Oppenheimer. Audeo also plans to undertake a secondary listing of CHESS Depository Instruments (CDIs) on the ASX. Pete Smith will become Audeo's CEO, while Charles Walker and Tracey Brown will become CFO and CSO, respectively. Smith and Walker will continue as CEO and CFO of Alchemia for a short time after the demerger is complete. Audeo is developing Alchemia's Hyaluronic Acid Chemotransport Technology ( HyACT) oncology programs, including HA-Irinotecan. The IV formulation of irinotecan and hyaluronic acid is in Phase III testing to treat metastatic colorectal cancer. ...